JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In Compliance with Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 we are forwarding herewith a copy of the Certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended 30th June, 2020. This is for your information & record. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NANDITA SINGHDesignation :- Company Secretary and Compliance Officer JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24 A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2020. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Material Impact Of COVID-19 Pandemic On The Company.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and advisory issued by the Securities and Exchange Board of India (SEBI) vide its circular SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020, we are submitting herewith the disclosure of material impact of COVID-19 pandemic on the operations and performance of the Company. This is for your information and records. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayJAGSONPAL PHARMACEUTICALS LTD. 2CINL74899DL1978PLC009181 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 64.04 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NANDITA SINGH Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: csnanditasingh@gamil.com Name of the Chief Financial Officer: SANJIV KUMAR DUDEJA Designation: CHIEF FINANCIAL OFFICER EmailId: sagar@jagsonpal.com Date: 26/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Reply To Clarification Sought By The Exchange.
Reply To Clarification Sought By The Exchange. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Reply To Clarification Sought By National Stock Exchange Of India Ltd On Price Movement.
With reference to the clarification sought by you, please note that the Company is in compliant with all the necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and all the material information/event which have bearing on the operation or performance of the Company which includes all price sensitive information are disseminated to the stock exchange well within the time by the Company. Further, please note that we do not have any information or announcement (including pending announcement) which in our opinion may have a bearing on the price behavior of the Scrip. Therefore the movement in the Share price of the Company is purely due to Market Conditions and absolutely market driven and management of the Company is in no way connected with any such movement of price. Hope this clarifies your query. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Clarification sought from Jagsonpal Pharmaceuticals Ltd
The Exchange has sought clarification from Jagsonpal Pharmaceuticals Ltd on June 24, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Submission Of Certificate Under Sub- Regulation 9 & 10 Regulation 40 Of The SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 For The Half Year Ended 31St March, 2020.
Certificates under Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In Compliance with Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 we are forwarding herewith a copy of the Certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended 31st March, 2020. This is for your information & record.